Baseline characteristics
| Characteristics . | n (%) . |
|---|---|
| Total | 43 (100) |
| Male sex | 26 (60) |
| Age (median, range), y | 35 (18-70) |
| Stage at diagnosis | |
| I-II | 17 (40) |
| III-IV | 26 (60) |
| Frontline regimen | |
| A(B)VD | 37 (86) |
| BV | 2 (5) |
| BV→ABVD (sequential) | 1 (2.3) |
| ABVD/BV | 1 (2.3) |
| ABVE | 1 (2.3) |
| BEACOPP escalated | 1 (2.3) |
| Stage at baseline | |
| I-II | 17 (40) |
| III-IV | 26 (60) |
| B symptoms at baseline | 15 (35) |
| Extranodal disease at baseline | 16 (37) |
| Bulky disease at baseline ( | 8 (19) |
| Prior radiation | 5 (12) |
| Primary refractory | 19 (44) |
| Relapsed | 24 (56) |
| Characteristics . | n (%) . |
|---|---|
| Total | 43 (100) |
| Male sex | 26 (60) |
| Age (median, range), y | 35 (18-70) |
| Stage at diagnosis | |
| I-II | 17 (40) |
| III-IV | 26 (60) |
| Frontline regimen | |
| A(B)VD | 37 (86) |
| BV | 2 (5) |
| BV→ABVD (sequential) | 1 (2.3) |
| ABVD/BV | 1 (2.3) |
| ABVE | 1 (2.3) |
| BEACOPP escalated | 1 (2.3) |
| Stage at baseline | |
| I-II | 17 (40) |
| III-IV | 26 (60) |
| B symptoms at baseline | 15 (35) |
| Extranodal disease at baseline | 16 (37) |
| Bulky disease at baseline ( | 8 (19) |
| Prior radiation | 5 (12) |
| Primary refractory | 19 (44) |
| Relapsed | 24 (56) |
ABVD, adriamycin, bleomycin, vinblastine, dexamethasone; ABVE+PC, adriamycin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide; BEACOPP, bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, prednisone, procarbazine.